| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
HWH International Inc. Common Stock
$1.86
-0.04 (-1.97%)
Market Cap
14.37 M
EPS
-0.33
P/E Ratio
-
Value Trade
11.48 M
-7.46 %
Week
30.99 %
1 Month
80.58 %
3 Month
39.85 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.98 K
52 Week Range
0.88 - 7.77
% held by Insiders
95.14 %
% held by Institutions
1.3 %
Enterprise Value
12.75 M
Total Shares
7.73 M
Short %
11.68 %
Float Shares
1.46 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
HWH Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HWH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HWH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-HWH
Sep 1, 2026▼ -2%today
HWH International Inc. Announces Executive Leadership Transition
HWH International Inc. has announced a leadership transition, with Chan Heng Fai stepping down as Chairman and CEO, effective September 1, 2026. He will be succeeded by Liu Ming Hui as Executive Chairman and Dr. Liu Ming Xing as CEO. Both incoming leaders bring significant experience from their roles at China Gas Holdings, aiming to enhance HWH's strategic direction.
Read more →-HWH
Sep 16, 2025▼ -6%on this news
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction The following unaudited pro forma condensed combined financial statements of HWH International Inc. present the combination of the historical fina
HWH International Inc. has released unaudited pro forma condensed combined financial statements reflecting the historical financial information of the company. These statements include adjustments in relation to the recent sale of a 70% stake in its subsidiary, Alset F&B One Pte. Ltd., for approximately $170,754 U.S. Dollars. The pro forma statements serve as an illustrative representation of the company's financial condition post-sale but are not indicative of actual results. The company continues to own a 20% stake in Alset F&B One post-transaction.
Read more →-HWH
Feb 20, 2025▼ -7.3%on this news
HWH International Inc. Announces Reverse Stock Split BETHESDA, MD
HWH International Inc. has announced a 1-for-5 reverse stock split, effective February 24, 2025, to ensure compliance with Nasdaq's minimum bid price requirements. The company's shares will continue to trade under the current symbol 'HWH.' Following the split, stockholders holding fractional shares will receive cash payments equivalent to their fractional interests. This decision was approved by the Company's stockholders and Board of Directors on January 16, 2025.
Read more →-HWH
Jan 12, 2024▼ -6.4%on this news· ran to -22% by day 3
ALSET CAPITAL ACQUISITION CORP. BALANCE SHEETS (Unaudited) August 31
Alset Capital Acquisition Corp.'s unaudited balance sheets as of August 31, 2023, reveal a significant decline in total assets to $22.08 million, down from $89.30 million a year earlier. The company recorded a net loss of $176,025 for the three months ending August 31, 2023, contrasting with a net income of $122,132 from the same period in 2022. While investment income has risen for the nine months ending August 2023, the overall financial position is weakened by increasing accumulated deficits.
Read more →-HWH
Jul 31, 2023UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than th
The United States Securities and Exchange Commission has received a proxy statement related to a proposed business combination involving HWH International Inc. and CAPITAL ACQUISITION CORP. This proxy supplement contains additional disclosures regarding newly established equity financing arrangements that will influence the share issuance during the business combination. The document emphasizes the importance of reviewing both this supplement and the definitive proxy statement for a comprehensive understanding of the implications of the proposal.
Read more →-HWH
Jul 21, 2023ALSET CAPITAL ACQUISITION CORP. ANNOUNCES POSTPONEMENT OF SPECIAL MEETING OF STOCKHOLDERS Bethesda, MD
Alset Capital Acquisition Corp. announced the postponement of its special meeting of stockholders, originally set for July 25, 2023, to August 1, 2023. The meeting will still address the approval of Alset's business combination with HWH International, Inc. Additionally, the deadline for stockholders to submit their shares for redemption regarding the business combination has been extended to July 28, 2023. Despite the change in timing, there are no modifications to the meeting's proposals or venue.
Read more →-HWH
Sep 12, 2022Alset Capital Acquisition Corp. Announces Execution of Merger Agreement with HWH International Inc. Bethesda, MD / Accesswire /
Capital Acquisition Corp. Announces Execution of Merger Agreement with HWH International Inc. MD / Accesswire / September 12, 2022 / Alset Capital Acquisition Corp. (NASDAQ: ACAX) ("ACAX"), a special purpose acquisition corporation sponsored by Alset Acquisition Sponsor LLC, a
Read more →-HWH
Feb 3, 2022REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of Alset Capital Acquisition Corp. Opinion on the Financial Statements We have audited the accompanying balance sheet of
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM the Shareholders and Board of Directors of Capital Acquisition Corp. on the Financial Statements have audited the accompanying balance sheet of Alset Capital Acquisition Corp.( the "Company") as of February 3, 2022, and the re
Read more →-HWH
Jan 31, 2022Alset Capital Acquisition Corp. Announces Pricing of $75,000,000 Initial Public Offering Bethesda, MD
Capital Acquisition Corp. Announces Pricing of $75,000,000 Initial Public Offering MD - January 31, 2022 - Alset Capital Acquisition Corp. (the "Company") announced today that it priced its initial public offering of $75,000,000, consisting of 7,500,000 units at $10.00 per unit
Read more →Competitive Position
How HWH ranks across every disease it competes inCompetitive Position is a premium feature
See how HWH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial